Prognosis of patients with coronary artery disease and diabetes — what to look for

Patients with coronary artery disease (CAD) and diabetes are identified as a high cardiovascular risk group both in Russia and abroad. Having similar paths of development and progression of atherosclerosis and atherothrombosis, these diseases potentiate each other's thrombogenesis mechanisms. As a result, cardiovascular ischemic events occur, making a significant contribution to the mortality rates of this group of patients. Influencing the risk of thrombus formation is one of the key links on the way to improving the prognosis of patients with CAD and diabetes. Modern antithrombotic therapy, including not only the antiplatelet agent aspirin, but also the anticoagulant rivaroxaban at a dose of 2,5 mg, allows for the maximum impact on the development of atherothrombosis, thereby reducing the risks of cardiovascular events and all-cause death. The aim of the review was to analyze the potential of reducing the all-cause death risk by prescribing the main drug groups that are part of the therapy of patients with CAD and diabetes.